Solid Biosciences update on clinical trials
Solid Biosciences has shared an update about its work to develop new treatments for Duchenne muscular dystrophy (DMD), in its INSPIRE DUCHENNE and IMPACT DUCHENNE studies.
The INSPIRE DUCHENNE study is testing its gene therapy, SGT-003, in children aged one to ten. So far, 33 children have received the treatment. The results show that the therapy has been well tolerated, with no serious safety concerns reported. Early signs suggest improvements in heart function and muscle health, and muscle biopsies show promising levels of micro-dystrophin.
Solid Biosciences has also started enrolling participants in its IMPACT DUCHENNE trial, a larger study taking place outside the United States. The first child has joined the trial, and dosing is expected to begin in early 2026. The study will start in Canada and Australia and aims to expand into Europe later this year, subject to regulatory approval.
The company plans to share more data from the INSPIRE DUCHENNE study in mid-2026 and will continue discussions with regulators about the next steps, including the possibility of accelerated approval.
Solid has issued a community letter, which you can read here. We will continue to share updates as they become available.